A randomized controlled trial investigating the survival benefit of dose-intensified multidrug combination chemotherapy (LSG9) for intermediate- or high-grade non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9002.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples